Greenwood Capital Associates’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-6,733
| Closed | -$265K | – | 242 |
|
|
2024
Q4 | $265K | Sell |
6,733
-233
| -3% | -$9.17K | 0.03% | 226 |
|
|
2024
Q3 | $327K | Sell |
6,966
-162
| -2% | -$7.61K | 0.04% | 208 |
|
|
2024
Q2 | $385K | Buy |
7,128
+434
| +6% | +$23.4K | 0.05% | 202 |
|
|
2024
Q1 | $456K | Sell |
6,694
-107
| -2% | -$7.29K | 0.06% | 206 |
|
|
2023
Q4 | $426K | Buy |
6,801
+1,306
| +24% | +$81.8K | 0.06% | 203 |
|
|
2023
Q3 | $249K | Buy |
5,495
+31
| +0.6% | +$1.41K | 0.04% | 234 |
|
|
2023
Q2 | $307K | Sell |
5,464
-167
| -3% | -$9.38K | 0.04% | 217 |
|
|
2023
Q1 | $255K | Sell |
5,631
-59,374
| -91% | -$2.69M | 0.04% | 218 |
|
|
2022
Q4 | $2.64M | Buy |
65,005
+4,950
| +8% | +$201K | 0.43% | 61 |
|
|
2022
Q3 | $3.93M | Buy |
+60,055
| New | +$3.93M | 0.67% | 49 |
|